Clinical trial · no report yet · Phase 2

hypo-FLAME 2.0

Hypofractionated Focal Lesion Ablative Microboost in prostatE Cancer 2.0

NCT04045717 ↗
Active, not recruiting
Universitaire Ziekenhuizen KU Leuven
Focused

We haven't built an HCP commentary report on hypo-FLAME 2.0 (Prostate Adenocarcinoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.

Indexed commentary on hypo-FLAME 2.0 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

Channel	Indexed
X threads	2
Bluesky threads	1

Indexed todayTypical once built

The trial

ClinicalTrials.gov

Official title: Hypofractionated Focal Lesion Ablative Microboost in prostatE Cancer 2.0
Phase: Phase 2
Status: Active, not recruiting
Conditions: Prostate Adenocarcinoma; Prostate Cancer; Prostate Neoplasm
Interventions: Hypo-FLAME 2.0 study
Arms: Hypo-FLAME 2.0 · Experimental
Enrollment: 124 (estimated)
Primary outcomes: Acute toxicity
Sponsor: Universitaire Ziekenhuizen KU Leuven with The Netherlands Cancer Institute, Radboud University Medical Center, Kom Op Tegen Kanker
Start: Apr 10, 2020
Primary completion: Jun 1, 2022
Results posted: No
Registry record: NCT04045717 · updated Dec 1, 2023

Publications

linked from the registry

De Cock L, Draulans C, Pos FJ, Isebaert S, De Roover R, van der Heide UA, Smeenk RJ, Kunze-Busch M, van der Voort van Zyp J, de Boer H, Kerkmeijer LGW, Haustermans K. From once-weekly to semi-weekly whole prostate gland stereotactic radiotherapy with focal boosting: Primary endpoint analysis of the multicenter phase II hypo-FLAME 2.0 trial. Radiother Oncol. 2023 Aug;185:109713. doi: 10.1016/j.radonc.2023.109713. Epub 2023 May 11. PubMed 37178932